92 terminated. 92 Phase 1, 41 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 92 | Terminated 92 |
| Phase 2 | 41 | Terminated 41 |
Follow Prostate Cancer: new trials by email Literature Review of Prostate Cancer trials Research Report on Prostate Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer Dapagliflozin - Prostate Cancer, Cancer of Prostate | Phase 1 | Terminated | Washington University School of Medicine | 5 | 2024-06-04 | 2026-06-30 |
| A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors VIO-01 - Advanced or Metastatic Solid Tumors, Breast Cancer | Phase 1 / Phase 2 | Terminated | Valerio Therapeutics | 6 | 2024-01-10 | 2025-03-17 |
| Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors TNG348, Olaparib - Breast Cancer, Ovarian Cancer | Phase 1 / Phase 2 | Terminated | Tango Therapeutics, Inc. | 7 | 2023-12-08 | 2024-08-13 |
| Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) XNW5004, KEYTRUDA® (pembrolizumab) 25 mg/mL Solution for Injection - Carcinoma, Squamous Cell Carcinoma of Head and Neck | Phase 1 / Phase 2 | Terminated | Evopoint Biosciences Inc. | 12 | 2023-09-20 | 2026-07-23 |
| Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer Darolutamide, Abemaciclib, GNRH-A Leuprolide Acetate - Metastatic Prostate Cancer, Non-metastatic Prostate Cancer | Phase 1 | Terminated | Praful Ravi, MB BCHir, MRCP | 9 | 2023-08-09 | 2026-10-15 |
| A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients Relugolix Pill, Ritonavir, Itraconazole - Prostate Cancer, Prostate Cancer Metastatic | Phase 1 | Terminated | University of Chicago | 60 | 2023-02-13 | 2024-09-19 |
| Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer ChAdOx1-PCAQ, MVA-PCAQ - Prostate Cancer | Phase 1 / Phase 2 | Terminated | Barinthus Biotherapeutics | 22 | 2023-01-30 | 2025-11-10 |
| Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose. Abiraterone Oral Tablet, Prednisone tablet, Drug Dairy/Log - Prostate Cancer, Prostate Adenocarcinoma | Phase 1 | Terminated | University of Chicago | 50 | 2023-01-24 | 2025-10-03 |
| NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors NUV-868, Olaparib, Enzalutamide - Advanced Solid Tumor, Ovarian Cancer | Phase 1 | Terminated | Nuvation Bio Inc. | 82 | 2022-03-29 | 2025-11-06 |
| EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC Enzalutamide, EPI-7386 with Enzalutamide - Prostate Cancer | Phase 1 / Phase 2 | Terminated | ESSA Pharmaceuticals | 77 | 2021-12-21 | 2025-02-28 |
| Study of PCUR-101 in Combination With ADT in Patients With mCRPC PCUR-101, Dutasteride 0.5 mg, Abiraterone and Prednisone - Prostate Cancer | Phase 1 | Terminated | Pellficure Pharmaceuticals, Inc | 7 | 2021-03-30 | 2024-04-10 |
| Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors NUV-422 - Glioma, Glioma, Malignant | Phase 1 | Terminated | Nuvation Bio Inc. | 74 | 2020-12-08 | 2023-07-14 |
| Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker Cyclophosphamide (Non-IMP), Fludarabine (Non-IMP), UniCAR02-T-pPSMA - Prostate Cancer | Phase 1 | Terminated | AvenCell Europe GmbH | 16 | 2020-11-23 | 2024-04-23 |
| Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. CYH33 - Ovarian Cancer, Breast Cancer | Phase 1 | Terminated | Haihe Biopharma Co., Ltd. | 24 | 2020-09-28 | 2024-03-21 |
| A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4. - Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer | Phase 1 / Phase 2 | Terminated | Genmab | 48 | 2020-07-15 | 2023-07-25 |
| Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer EPI-7386 (QD), EPI-7386 (BID), Abiraterone acetate - Prostate Cancer | Phase 1 | Terminated | ESSA Pharmaceuticals | 71 | 2020-06-23 | 2025-02-28 |
| Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer Enzalutamide Liquid, Enzalutamide Capsule - Prostate Cancer | Phase 1 | Terminated | National Cancer Institute (NCI) | 1 | 2020-03-10 | 2021-05-10 |
| P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) P-PSMA-101 CAR-T cells, Rimiducid - Prostatic Neoplasms, Castration-Resistant, Neoplasms by Histologic Type | Phase 1 | Terminated | Poseida Therapeutics, Inc. | 40 | 2020-02-28 | 2025-02-17 |
| PK and Dose Escalation and Expansion Study of DST-2970 Abiraterone Acetate, Prednisone 5Mg Tab, DST-2970 (Abiraterone) - Prostate Cancer | Phase 1 | Terminated | DisperSol Technologies, LLC | 26 | 2020-01-31 | 2024-10-17 |
| PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy) BNT112, Cemiplimab - Prostate Cancer | Phase 1 / Phase 2 | Terminated | BioNTech SE | 75 | 2019-12-19 | 2025-03-20 |
Showing 20 of 92. Sign in to see all of them.
Prostatic Neoplasms (92) · Breast Neoplasms (11) · Ovarian Neoplasms (8) · Carcinoma, Non-Small-Cell Lung (7) · Neoplasm Metastasis (5) · Neoplasms (5) · Carcinoma, Transitional Cell (4) · Lung Neoplasms (4) · Endometrial Neoplasms (3) · Pancreatic Neoplasms (3) · Prostatic Neoplasms, Castration-Resistant (3) · Salivary Gland Neoplasms (3) · Sarcoma (3) · Squamous Cell Carcinoma of Head and Neck (3) · Stomach Neoplasms (3)
Genital Diseases (92) · Male Urogenital Diseases (92) · Urogenital Diseases (92) · Genital Diseases, Male (91) · Prostatic Diseases (91) · Genital Neoplasms, Male (90) · Neoplasms by Site (90) · Urogenital Neoplasms (90) · Neoplasms (87) · Female Urogenital Diseases (17) · Female Urogenital Diseases and Pregnancy Complications (17) · Breast Diseases (12) · Genital Diseases, Female (12) · Genital Neoplasms, Female (12) · Skin Diseases (12)
Docetaxel (14) · Prednisone (9) · Leuprolide (4) · abiraterone (4) · bicalutamide (4) · enzalutamide (4) · olaparib (4) · Abiraterone Acetate (3) · Cyclophosphamide (3) · Radiation (3) · Biopsy (2) · Dutasteride (2) · Immunohistochemistry (2) · Magnetic Resonance Spectroscopy (2) · Pyruvic Acid (2)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (5) · Medical University of South Carolina (3) · NYU Langone Health (3) · National Cancer Institute (NCI) (3) · University of Chicago (3) · University of Michigan Rogel Cancer Center (3) · Agennix (2) · AvenCell Europe GmbH (2) · Dana-Farber Cancer Institute (2) · ESSA Pharmaceuticals (2) · M.D. Anderson Cancer Center (2) · Nuvation Bio Inc. (2) · Rahul Aggarwal (2) · Sandy Srinivas (2) · University of California, San Francisco (2)
United States (79) · Australia (6) · Canada (6) · United Kingdom (6) · France (4) · Germany (4) · China (3) · Austria (2) · Netherlands (2) · Spain (2) · Taiwan (2) · Belgium (1) · Czechia (1) · Denmark (1) · Finland (1)
Glenn Bubley, MD (2) · Rahul Aggarwal, MD (2) · Samuel Denmeade, MD (2) · Adam Crystal, MD, PhD (1) · Adam Dicker, MD (1) · Adam Dicker, MD, PhD (1) · Ajjai Alva, MD (1) · Alexander Philipovskiy, M.D., PhD (1) · Amado Zurita, MD (1) · Andrew S. Kraft, MD (1) · Andrew Stephens, MD, PhD (1) · Anish Thomas, M.D. (1) · Anna Ferrari, MD (1) · Anthony Fyles, MD (1)
PMID 22326922, PMID 25974235, PMID 32897402, PMID 33015525, PMID 33465252, PMID 34333820, PMID 35058326, PMID 38885312, PMID 39168098, PMID 39473059, PMID 39990653, PMID 40906325, PMID 42820295
2019 (2), 2009 (1), 2014 (1), 2017 (1), 2018 (1), P50CA091956 (1), P50CA186786 (1), P50CA272390 (1), R01CA082661 (1), R01CA091763 (1), R01CA166655 (1), R01CA183071 (1), U01CA140204 (1), U10CA032102 (1)